Walter M Gregory

Walter M Gregory

UNVERIFIED PROFILE

Are you Walter M Gregory?   Register this Author

Register author
Walter M Gregory

Walter M Gregory

Publications by authors named "Walter M Gregory"

Are you Walter M Gregory?   Register this Author

51Publications

1198Reads

44Profile Views

Recommendations on multiple testing adjustment in multi-arm trials with a shared control group.

Stat Methods Med Res 2018 May 19;27(5):1513-1530. Epub 2016 Sep 19.

1 Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0962280216664759DOI Listing
May 2018

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.

Br J Haematol 2017 07 1;178(2):220-230. Epub 2017 Jun 1.

Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14753DOI Listing
July 2017

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

J Clin Oncol 2015 Nov 17;33(33):3911-20. Epub 2015 Aug 17.

Brian A. Walker, Eileen M. Boyle, Christopher P. Wardell, Alex Murison, Dil B. Begum, Nasrin M. Dahir, Paula Z. Proszek, David C. Johnson, Martin F. Kaiser, Lorenzo Melchor, Lauren I. Aronson, Charlotte Pawlyn, Fabio Mirabella, John R. Jones, Annamaria Brioli, Faith E. Davies, and Gareth J. Morgan, The Institute of Cancer Research, London; Matthew Scales, The Institute of Cancer Research, Surrey; David A. Cairns, Walter M. Gregory, and Ana Quartilho, University of Leeds; Gordon Cook, St James's University Hospital, Leeds; Mark T. Drayson, University of Birmingham, Birmingham; Nigel Russell, Nottingham University Hospital, Nottingham; Graham H. Jackson, Newcastle University, Newcastle upon Tyne, United Kingdom; Aneta Mikulasova, Masaryk University, Brno, Czech Republic; and Xavier Leleu, Hôpital C. Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.1503
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.1503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485456PMC
November 2015

Adding a treatment arm to an ongoing clinical trial: a review of methodology and practice.

Trials 2015 Apr 22;16:179. Epub 2015 Apr 22.

Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, LS2 9JT, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-015-0697-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457999PMC
April 2015

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.

J Clin Oncol 2014 Apr 3;32(10):1074-83. Epub 2014 Mar 3.

Virginie F. Viprey and Susan A. Burchill, Leeds Institute of Cancer and Pathology; Walter M. Gregory, Clinical Trials Research Unit, University of Leeds, Leeds; Penelope Brock, Great Ormond Street Hospital, London; Andrew D. Pearson, Institute of Cancer Research/Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom; Maria V. Corrias and Sandro Dallorso, Gaslini Institute, Genoa; Roberto Luksch, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milano, Italy; Andrei Tchirkov, Centre Hospitalier Universitaire Clermont-Ferrand and Clermont Université, Université d'Auvergne, Clermont-Ferrand; Dominique Valteau-Couanet, Institut Gustave Roussy, Villejuif, France; Katrien Swerts and Genevieve Laureys, University Hospital Ghent, Ghent, Belgium; Ales Vicha, Charles University and University Hospital Motol, Prague, Czech Republic; Vassilios Papadakis, Agia Sofia Children's Hospital, Athens, Greece; and Ruth Ladenstein, Children's Cancer Research Institute/St Anna Children's Hospital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.3604DOI Listing
April 2014

Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Clin Cancer Res 2013 Nov 30;19(21):6030-8. Epub 2013 Aug 30.

Authors' Affiliations: Institute of Cancer Research, Royal Marsden Hospital, London; Clinical Trials Research Unit, University of Leeds; St James's University Hospital, Leeds; University of Birmingham, Birmingham; Wessex Regional Genetics Laboratory, University of Southampton, Salisbury; and University of Newcastle, Newcastle-upon-Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2013/08/
Web Search
http://clincancerres.aacrjournals.org/content/19/21/6030.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-3211DOI Listing
November 2013

The impact of response on bone-directed therapy in patients with multiple myeloma.

Blood 2013 Oct 23;122(17):2974-7. Epub 2013 Aug 23.

Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-04-498139DOI Listing
October 2013

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Leuk Lymphoma 2013 Sep 23;54(9):1975-81. Epub 2013 Jan 23.

Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.760736DOI Listing
September 2013

Improved risk stratification in myeloma using a microRNA-based classifier.

Br J Haematol 2013 Aug 30;162(3):348-59. Epub 2013 May 30.

Section of Haemato-Oncology, Institute of Cancer Research, Sutton, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12394DOI Listing
August 2013

Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.

Br J Haematol 2013 Apr 29;161(2):291-4. Epub 2013 Jan 29.

Division of Molecular Pathology, Haemato-Oncology Research Unit, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12218DOI Listing
April 2013

A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.

Clin Cancer Res 2011 Oct 19;17(19):6347-55. Epub 2011 Aug 19.

Section of Haemato-Oncology Research Unit, Division of Molecular Pathology, Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-0994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866998PMC
October 2011

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.

Clin Cancer Res 2009 Oct 29;15(19):6008-17. Epub 2009 Sep 29.

Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0898DOI Listing
October 2009